Fecha de publicación: -- Fuente: WIPO "tomato" Disclosed herein are polypeptides that include human complement factor B analogs and fusion proteins formed therefrom. The complement factor B analogs typically have one or more mutations at a factor D cleavage site, and optionally one or more mutations at C3B binding sites or a mutation of a free cysteine site. Also disclosed herein are pharmaceutical compositions containing a complement factor B analog or a complement factor B analog Fc fusion protein, as a homodimer, multimer, or heterodimer. These pharmaceutical compositions include nucleic acids, viral vectors, or cells that encode or express the disclosed composition. Methods for treating complement-mediated diseases are also disclosed and can include administering the pharmaceutical compositions to subjects for modulation of complement activity and treatment of disease symptoms associated with complement pathway dysfunction.